Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chloramphenicol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.90 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.90 |
| ▸ | RPS17 | P08708 | 1/20 | 0.90 |
| ▸ | RPSA | P08865 | 1/20 | 0.90 |
| ▸ | RPS2 | P15880 | 1/20 | 0.90 |
| ▸ | RPL35A | P18077 | 1/20 | 0.90 |
| ▸ | RPL7 | P18124 | 1/20 | 0.90 |
| ▸ | RPL17 | P18621 | 1/20 | 0.90 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.90 |
| ▸ | RPS3 | P23396 | 1/20 | 0.90 |
| ▸ | RPS12 | P25398 | 1/20 | 0.90 |
| ▸ | RPL13 | P26373 | 1/20 | 0.90 |
| ▸ | RPL10 | P27635 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloramphenicol SCHEMBL4262903 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL28181476 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL49057 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL16111 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL29557257 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL4295048 | 1.00 | LMNA (1.00) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL11131056 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL41042 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL20531030 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 | |
| Chloramphenicol SCHEMBL28607485 | 0.99 | LMNA (0.97) | LMNACYP3A4TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401554-A1 | USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES | CORNELL UNIVERSITY | 2022-12-22 | — | — | US | claimed |
| WO-2022164850-A1 | COMPOUNDS TO PREVENT OR TREAT SARS-CoV-2 VARIANT INFECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022160971-A1 | CONCENTRATE CONTAINING POORLY SOLUBLE DRUG, AND EMULSION PREPARED THEREFROM | 北京德立福瑞医药科技有限公司 | 2022-08-04 | — | — | WO | claimed |
| CN-105497043-B | A kind of externally applied drug and preparation method thereof for treating skin eczema and eczema-like dermatitis | 汶上县皮肤病防治站 | 2019-01-18 | — | — | CN | claimed |
| US-9227999-B2 | Antimicrobial cationic peptides and formulations thereof | CARRUS CAPITAL CORPORATION (CA) | 2016-01-05 | — | — | US | claimed |
| EP-1951213-B1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LTD (GB) | 2012-11-14 | — | — | EP | claimed |
| EP-1143950-B1 | TOPICAL APPLICATION PRODUCTS AGAINST ONYCHOMYCOSES | BIOEQUAL AG (CH) | 2005-03-09 | — | — | EP | claimed |
| US-5192552-A | Capsules coated with ethyl cellulose and sulfosuccinate in cyclohexane | EGIS GYOGYSZERGYAR (HU) | 1993-03-09 | — | — | US | claimed |
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260077188-A1 | MEDICAL IMPLANT FOR RELEASE OF AN AFFINITY-BOUND DRUG IN AN ELECTRIC FIELD | TECHNISCHE UNIVERSITAET MUENCHEN, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4710987-A1 | MEDICAL IMPLANT FOR RELEASE OF AN AFFINITY-BOUND DRUG IN AN ELECTRIC FIELD | Technische Universität München, in Vertretung des Freistaats Bayern (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260048114-A1 | INFLUENZA VIRUS VACCINATION REGIMENS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260042867-A1 | ANTIBODY REPURPOSING | SRI INTERNATIONAL (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4241785-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-01-28 | — | — | EP | disclosed |
| US-4684728-A | Solubilizing biologically active compounds with reactive hydrogen atoms | BAYER AKTIENGESELLSCHAFT (DE) | 1987-08-04 | — | — | US | disclosed |
| EP-0137212-A2 | Ointment bases and ointments | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-04-17 | — | — | EP | disclosed |
| WO-1983002055-A1 | QUAIL'S EGG BASED STABILIZED COMPOSITIONS, PARTICULARLY FOR COSMETIC PURPOSES | INTERKEMIA VEGYIPARI GAZDASAGI (HU) | 1983-06-23 | — | — | WO | disclosed |
| EP-0014263-B1 | METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY | BAYER AG (DE) | 1982-05-05 | — | — | EP | disclosed |
| US-4324799-A | Fungicidal thioglycolic acid anilides, processes for their manufacture and pesticidal compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-04-13 | — | — | US | disclosed |
| EP-0014263-A2 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401554-A1 | USE OF MEMBRANE INHIBITORS TO ENHANCE VACCINE DEVELOPMENT AGAINST ENVELOPED VIRUSES | PIGS, VMA21, FURIN | LMNA 414/4885CYP3A4 3524/4885TSHR 4676/4885 |
| US-20260048114-A1 | INFLUENZA VIRUS VACCINATION REGIMENS | H1-3, CD81, FUT8 | LMNA 3033/4885CYP3A4 2880/4885TSHR 365/4885 |
| US-20260077188-A1 | MEDICAL IMPLANT FOR RELEASE OF AN AFFINITY-BOUND DRUG IN AN ELECTRIC FIELD | CD69, CD274, STIM2 | LMNA 3476/4885CYP3A4 148/4885TSHR 1105/4885 |
| US-20260042867-A1 | ANTIBODY REPURPOSING | CD47, SSB, IGSF11 | LMNA 2830/4885CYP3A4 4191/4885TSHR 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.